Melanoma TrialFinder

For patients

Find a trial

22 trials in 47 locations

V940-001: A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma

Currently, patients with stage 2B, 2C, 3 or 4 cutaneous melanoma who have had their melanoma removed by surgery, are offered adjuvant treatment with immunotherapy (pembrolizumab or nivolumab) if they are deemed as having a high-risk of their melanoma returning.This trial aims to investigate if receiving combination treatment with V940 and pembrolizumab is better than receiving pembrolizumab alone to prevent the melanoma from returning in these patients.The trial also aims to look at how [...]

Locations: St James's University Hospital, The Christie NHS Foundation Trust, Norfolk and Norwich University Hospital, Oxford University Hospitals NHS Foundation Trust, Western General Hospital, Bristol Haematology and Oncology Centre, Cambridge University Hospitals NHS Trust, University College Hospitals NHS Foundation Trust, The Royal Marsden Hospital (LONDON)

PORTSIDE: A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With BRAF Positive Advanced Melanoma

Currently, patients who have BRAF positive, cutaneous melanoma can receive treatment with immunotherapy (nivolumab with or without ipilimumab or pembrolizumab), or with targeted treatment (dabrafenib and trametinib or encorafenib and binimetinib).The purpose of this study is to investigate if it is more effective to give a combination of three treatments (encorafenib, binimetinib, pembrolizumab) compared to the standard combination of two immunotherapy treatments (ipilimumab and nivolumab) for patients who have advanced melanoma that has progressed [...]

Locations: Nottingham University Hospitals NHS Trust, The Royal Marsden Hospital (LONDON), The Royal Marsden Hospital (SURREY)

RELATIVITY-127: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Relatlimab-nivolumab is a current standard immunotherapy treatment available to treat advanced melanoma in patients who haven’t previously received treatment.The trial aims to investigate if giving the immunotherapy treatment of relatlimab-nivolumab is as effective when given by subcutaneous injection (i.e. with a small injection that goes under the skin) as it is when it is given by intravenous infusion (i.e., into a vein in the arm), which is the current standard route.Researchers want to look [...]

Locations: Churchill Hospital, The Royal Marsden Hospital (LONDON), Freeman Hospital

HARMONY ADJUVANT STUDY: A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Currently, patients with stage 2C, 3 or 4 cutaneous melanoma or mucosal melanoma who have had their melanoma removed by surgery, are offered adjuvant treatment with immunotherapy (pembrolizumab or nivolumab) if doctors think there is a high-risk of their melanoma returning.This trial aims to investigate if receiving combination treatment immunotherapy with fianlimab and cemiplimab is better than receiving pembrolizumab alone to prevent the melanoma from returning in these patients.The trial also aims to look [...]

Locations: The Christie NHS Foundation Trust, Western General Hospital, Barts Health NHS Trust, Musgrove Park Hospital, Royal Devon and Exeter Hospital (Wonford), The Royal Marsden Hospital (LONDON), Bristol Haematology and Oncology Centre

THETIS (ATX-ME-001): ATL001 in Patients with Metastatic or Recurrent Melanoma

The trial aims to investigate how safe ATL001 is when it is used to treat melanoma and if patients experience any adverse events with the treatment.The trial also aims to measure how effective ATL001 is for treating melanoma, and how well it works when given with high or low-dose interleukin-2 (Il-2) or in combination with nivolumab immunotherapy ATL001 is made up of cells taken from your own melanoma, known as clonal neoantigen reactive T [...]

Locations: University College London Hospital (UCLH), The Royal Marsden Hospital (LONDON), Cambridge University Hospitals NHS Foundation Trust, Guys and St Thomas's NHS Foundation Trust, University Hospital Southampton, Freeman Hospital, The Christie NHS Foundation Trust

R3767-ONC-2011: Clinical Study of Fianlimab in Combination with Cemiplimab vs Cemiplimab vs Pembrolizumab in Adolescent and Adult Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This trial aims to investigate whether the combination treatment of fianlimab and cemiplimab or cemiplimab as monotherapy are more effective at treating advanced melanoma compared to the current standard immunotherapy treatment, pembrolizumab. The trial also wants to look at how well patients tolerate the combination treatment of fianlimab and cemiplimab or cemiplimab alone, for example, if they experience any side effects.Fianlimab is an experimental immunotherapy treatment that stimulates the body’s natural defence (immune system) [...]

Locations: St James's University Hospital, Castle Hill Hospital, Royal Surrey County Hospital, Royal Devon and Exeter Hospital

DANTE: Duration of Anti-PD1 therapy for melanoma

At the moment, clinicians aren’t sure how long to give PD-1 inhibitor treatment for to patients with advanced melanoma. The current practice is to treat for at least two years if the patient continues to benefit and can tolerate treatment. However, the treatment seems to make the most difference within the first year and there is evidence to suggest that the treatment could be as effective and cause fewer side effects if it [...]

Locations: This trial is no longer recruiting new patients

A UK qualitative study: Identifying patient research priorities in melanoma

Rapid improvements in melanoma care over the last 10 years, due to targeted and immunotherapy treatments, have influenced the type of research that is being carried out for melanoma. It is important to make sure that research benefits patients and so this project plans to interview patients across the UK to find out their views. Researchers will recruit a mix of participants of different gender, age, ethnicity, deprivation, disability, geographical region, and tumour stage [...]

Locations: Anyone in the UK can take part.

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

This study aims to better understand how genes as well as the immune system affect the development of melanoma. Researchers hope that the results could improve how melanoma is detected and also lead to the development of new treatments for melanoma.The early stages of melanoma can be treated effectively by using surgery to remove the melanoma, but no cure is available at the moment in more advanced melanoma. Doctors currently don’t know what causes [...]

Locations: Guy's and St Thomas' NHS Trust

MelMarT-II: Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

The trial aims to look at how long patients stay free from melanoma after different types of surgery to remove the disease. A wide local excision involves removing an extra "safety margin" of skin around the original melanoma site, to make sure that any remaining scattered melanoma tumour cells that may have been left behind after the first biopsy/surgery are removed. At the moment melanoma specialists don’t know the ideal width of excision [...]

Locations: The Christie NHS Foundation Trust, Guys and St Thomas' NHS Foundation Trust, Royal Free London NHS Foundation Trust, Royal Preston Hospital, Imperial College Healthcare NHS Trust, Royal Cornwall Hospital, Nottingham University Hospitals NHS Trust, Oxford University Hospitals NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Trust, Hull University Teaching Hospitals NHS Trust, North Bristol NHS Trust, Norfolk and Norwich University Hospital, Mersey and West Lancashire Teaching Hospitals NHS Trust, St George's University Hospitals NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital, University Hospitals Birmingham NHS Foundation Trust, Mid and South Essex NHS Trust

MITRE: Microbiome Immunotherapy Toxicity and Response Evaluation

The MITRE study aims to investigate whether there is a gut microbiome ‘signature’ (pattern) which can predict which patients receiving immune checkpoint inhibitors are likely to respond to treatment.The study also aims find out whether there is a link between the gut microbiome and risk of severe side effects associated with immune checkpoint inhibitor treatment. Gut Microbiome: People have hundreds of thousands of different types of natural bacteria living in the gastrointestinal tract, which [...]

Locations: Velindre Cancer Centre (Cardiff), Weston Park Hospital (Sheffield), Addenbrookes Hospital (Cambridge), Royal Surrey County Hospital, , Western General Hospital (Edinburgh), Royal Cornwall Hospital, Somerset NHS Foundation Trust, The Queen Elizabeth Hospital King's Lynn, Bristol Haematology and Oncology Centre, Poole Hospital, University Hospital Southampton, Royal United Hospital Bath, Royal Bournemouth Hospital

MAAM Study: Microwave Ablation in Advanced Melanoma Study

This trial aims to investigate if Microwave ablation (MWA) can be used to destroy and remove cutaneous melanoma metastases and also if it can help to stimulate the body’s natural defence ( immune system ) to attack the melanoma cells.This trial also aims to look at how patients tolerate the MWA treatment, through questionnaires and asking the patient to write notes in a pain diary.Microwave ablation (MWA) is a process that creates heat from [...]

Locations: University Hospital Southampton

ARTISTRY-6: Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma

The trial aims to investigate how effective nemvaleukin alfa is at treating unresectable and/or metastatic melanoma in patients who have previously received immunotherapy treatment with a PD-1 inhibitor for their melanoma.The trial also aims to look at how well patients cope with the treatment, for example, if they experience any side effects.The researchers also want to see if there is any difference to how well the drug works if the nemvaleukin alfa is given [...]

Locations: Oxford University Hospitals NHS Foundation Trust, THE ROYAL MARSDEN HOSPITAL (LONDON), The Christie NHS Foundation Trust

PREMIUM: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

Currently patients with resectable stage 3 or stage 4 cutaneous melanoma are offered 1 year of adjuvant treatment after surgery. This is to reduce the risk of the melanoma returning. The treatment they are offered could be immunotherapy, or if the melanoma has a BRAF positive mutation, targeted therapy.This study aims to investigate if giving targeted treatment to patients with BRAF positive cutaneous melanoma before resection surgery ( neoadjuvant treatment ), as well as [...]

Locations: Cambridge University Hospitals NHS Trust

: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

This observational study aims to investigate how many people develop a herpetic infection for up to 5 years after the first IMLYGIC® dose.The study also aims to look at if close contacts of the patients, or healthcare professionals that treated them, develop a herpetic infection for up to 5 years after the treatment.IMLYGIC® (brand name) also known as Talimogene Laherparepvec or T-VEC (generic/drug name) is made from a genetically modified form of the herpes [...]

Locations: The Royal Marsden Hospital (LONDON), Cheltenham General Hospital, Musgrove Park Hospital, Churchill Hospital, Guy's Hospital

REFINE: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers

Currently, patients with advanced melanoma will receive immunotherapy treatment with either ipilimumab + nivolumab or pembrolizumab. They receive this treatment as an infusion into the vein (e.g. in the arm), in a hospital or clinic, every 3 or 6 weeks for up to 2 years.Researchers think that it is likely that immunotherapy drugs work for a longer period of time than originally thought. This means it may be possible to give the drugs less [...]

Locations: Western General Hospital, The Beatson West of Scotland Cancer Centre, The Royal Marsden Hospital (SURREY), The Royal Marsden Hospital (LONDON), Musgrove Park Hospital, Royal Preston Hospital, Addenbrooke's Hospital, The Queen Alexandra Hospital, Velindre Cancer Centre

IOV-COM-202: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

For unresectable or metastatic melanoma, patients currently receive standard of care treatment with immunotherapy.This trial aims to investigate if an experimental treatment called Tumour-Infiltrating Lymphocyte (TIL) therapy (lifileucel) together with pembrolizumab can be effective as a first-line treatment for patients with advanced melanoma. The trial also aims to look at how safe these treatment combinations are, for example, if the patient experiences any side effects.LN 144/lifileucel (TIL therapy) is made when specific cells (TILs) [...]

Locations: The Royal Marsden Hospital (LONDON)

TebeMRD: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

This trial aims to look at how to treat patients with resected cutaneous melanoma who are thought to have a medium or high risk of the melanoma coming back, or patients with a diagnosis of uveal melanoma.This research will use a new blood test to see if there are any tiny amounts of melanoma cells in the body, which wouldn’t normally be seen on standard CT scans. It is thought that this blood test [...]

Locations: The Beatson West of Scotland Cancer Centre, Mount Vernon Cancer Centre, Weston Park Hospital (SCREENING ONLY - treatment would be at another hospital on this list), The Clatterbridge Cancer Centre, The Christie NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Cambridge University Hospitals NHS Trust (SCREENING ONLY - treatment would be at Oxford)

TEBE-AM: Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma

Currently, if a patient with advanced melanoma has disease progression during or after they receive treatment with immunotherapy, there aren’t many more available standard treatment options that are proven to be very effective. If the patient has a BRAF positive mutation, they can then be treated with targeted therapy, and if they have disease progression after this, they are left with few treatment options.This trial aims to investigate how effective treatment with tebentafusp or [...]

Locations: Queen Elizabeth Hospital Birmingham, Mount Vernon Hospital, Addenbrookes Hospital

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals in the UK to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. Biosamples are small parts of tissue that are removed from the ocular tumour so that doctors or researchers can analyse them.The biobank aims to build a valuable collection that will be used [...]

Locations: The Liverpool Ocular Oncology Centre

MYMELANOMA: The MyMelanoma Research Study

The MyMelanoma project aims to build the world’s biggest melanoma database which will support research into melanoma all over the world.There are currently many researchers all over the world working to make things better for melanoma patients, however they are mostly working on small studies. In order to make faster progress these researchers need more information, both more detailed and from a greater number of people, and MyMelanoma will provide that data.The MyMelanoma project [...]

Locations: This is an online study; anyone in the UK can take part.

The SCOPE Study: The SCOPE Study: SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma

The trial aims to investigate if SCIB1 or iSCIB1+ can be used safely as a combination treatment with current standard immunotherapy treatments, nivolumab with ipilimumab or pembrolizumab.The trial also wants to look at how effective the combination treatment is at treating melanoma.SCIB1 is an experimental therapeutic cancer vaccine. SCIB1 only has the potential to work in patients with certain tissue (HLA) types, and this needs to be tested before patients receive the treatment. SCIB1 [...]

Locations: Guys and St Thomas' NHS Foundation Trust, University Hospital Southampton, Royal Free London NHS Foundation Trust, Derriford Hospital, Royal Preston Hospital, Weston Park Hospital, Mount Vernon Hospital, East and North Hertfordshire NHS Trust, Oxford University Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Somerset NHS Foundation Trust, Velindre University NHS Trust